CAMP4 Therapeutics Corporation Common Stock (CAMP)

• Market cap: $53.4M
• 1 day: -18.46%
• 5 days: 57.74%
• 1 month: 58.68%
• 3 months: 82.76%
• 6 months: -50.65%
• Year to date: -46.25%
• 1 year: -75.28%
• 5 years: -75.28%
• 10 years: -75.28%
• Sector: Healthcare
• Industry: Biotechnology

About: Camp4 Therapeutics Corp is a clinical stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. It focuses on genetic diseases of the central nervous system and liver. The group's pipeline products are CMP-CPS-001 and CMP-SYNGAP.

Employees: 55

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

4.63% less ownership

Funds ownership: 62.88% [Q1] → 58.25% (-4.63%) [Q2]

25% less funds holding in top 10

Funds holding in top 10: 4 [Q1] → 3 (-1) [Q2]

26% less funds holding

Funds holding: 39 [Q1] → 29 (-10) [Q2]

45% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 11

59% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 17

66% less capital invested

Capital invested by funds: $50.7M [Q1] → $17M (-$33.7M) [Q2]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $12
• Avg. target: $12
• High target: $12

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Piper Sandler Edward Tenthoff

$12

Overweight Maintained

15 Sep 2025